Does intermittent intravenous outpatient administration of levosimendan reduce NT-proBNP, worsening of HRQoL, and heart failure hospitalizations in ambulatory patients with advanced systolic heart failure?
Ambulatory patients with advanced systolic heart failure
Intermittent intravenous outpatient administration of levosimendan
Plasma concentrations of NT-proBNP, worsening of health-related quality of life (HRQoL), and hospitalisation for heart failure
In a small pilot study, intermittent outpatient intravenous levosimendan showed potential benefits in reducing NT-proBNP, preventing HRQoL deterioration, and reducing hospitalizations in advanced systolic heart failure.
In this small pilot study, intermittent administration of levosimendan to ambulatory patients with advanced systolic heart failure reduced plasma concentrations of NT-proBNP, worsening of HRQoL and hospitalisation for heart failure. The efficacy and safety of this intervention should be confirmed in larger trials.
Building similarity graph...
Analyzing shared references across papers
Loading...
Josep Comín‐Colet
Heart Failure & Transplant
Nicolás Manito
Bellvitge University Hospital
Javier Segovia
Heart Failure & Transplant
European Journal of Heart Failure
Universitat de Barcelona
Universitat Autònoma de Barcelona
Hospital de Sant Pau
Building similarity graph...
Analyzing shared references across papers
Loading...
Comín‐Colet et al. (Tue,) studied this question.
synapsesocial.com/papers/69d56ec875589c71d767d64a — DOI: https://doi.org/10.1002/ejhf.1145